Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial Article Swipe

PDF

Michael A. Postow , Ryan J. Sullivan , Amita Patnaik , Ezra E.W. Cohen , Conor Steuer , Martin Gutierrez , Robert Ilaria , Brenda O’Connell , Joanna Peng , Nora Zizlsperger , Anthony W. Tolcher , Jedd D. Wolchok ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.30706743

Summary of anti-tumor activity endpoints in patients treated with eganelisib monotherapy and combination therapy

Related Topics

Su From So

My Face Hurts From Smiling

From Zero

2020 Summer Olympics Medal Table

Blowing From A Gun

From Bureaucrat To Villainess

Scenes From A Marriage

Table Of Handgun And Rifle Cartridges

Human From Today

Tales From The Darkside

From Genesis To Revelation

The Man From Snowy River (1982 Film)

From Justin To Kelly

Radiation Effects From The Fukushima Daiichi Nuclear Disaster

From Me To You

Concepts

No concepts available.

Metadata

Type: article
Landing Page: https://doi.org/10.1158/1078-0432.30706743
PDF: https://aacr.figshare.com/articles/journal_contribution/Table_S2_from_Eganelisib_a_First-in-Class_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors_Results_of_the_Phase_1_1b_MARIO-1_Trial/30706743/1/files/59831172.pdf
OA Status: gold
OpenAlex ID: https://openalex.org/W4416672025

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4416672025

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.30706743

Digital Object Identifier
Title: Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

Work title
Type: article

OpenAlex work type
Publication year: 2025

Year of publication
Publication date: 2025-11-25

Full publication date if available
Authors: Michael A. Postow, Ryan J. Sullivan, Amita Patnaik, Ezra E.W. Cohen, Conor Steuer, Martin Gutierrez, Robert Ilaria, Brenda O’Connell, Joanna Peng, Nora Zizlsperger, Anthony W. Tolcher, Jedd D. Wolchok

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.30706743

Publisher landing page
PDF URL: https://aacr.figshare.com/articles/journal_contribution/Table_S2_from_Eganelisib_a_First-in-Class_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors_Results_of_the_Phase_1_1b_MARIO-1_Trial/30706743/1/files/59831172.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://aacr.figshare.com/articles/journal_contribution/Table_S2_from_Eganelisib_a_First-in-Class_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors_Results_of_the_Phase_1_1b_MARIO-1_Trial/30706743/1/files/59831172.pdf

Direct OA link when available
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W4416672025
doi	https://doi.org/10.1158/1078-0432.30706743
ids.doi	https://doi.org/10.1158/1078-0432.30706743
ids.openalex	https://openalex.org/W4416672025
fwci
type	article
title	Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
is_xpac	False
apc_list
apc_paid
language
locations[0].id	doi:10.1158/1078-0432.30706743
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url	https://aacr.figshare.com/articles/journal_contribution/Table_S2_from_Eganelisib_a_First-in-Class_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors_Results_of_the_Phase_1_1b_MARIO-1_Trial/30706743/1/files/59831172.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.30706743
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5011325668
authorships[0].author.orcid	https://orcid.org/0000-0002-3367-7961
authorships[0].author.display_name	Michael A. Postow
authorships[0].author_position	middle
authorships[0].raw_author_name	Michael Postow
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5008479799
authorships[1].author.orcid	https://orcid.org/0000-0001-5344-6645
authorships[1].author.display_name	Ryan J. Sullivan
authorships[1].author_position	middle
authorships[1].raw_author_name	Ryan Sullivan
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5070570779
authorships[2].author.orcid	https://orcid.org/0000-0002-4144-2193
authorships[2].author.display_name	Amita Patnaik
authorships[2].author_position	middle
authorships[2].raw_author_name	Amita Patnaik
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5001334189
authorships[3].author.orcid	https://orcid.org/0000-0002-9872-6242
authorships[3].author.display_name	Ezra E.W. Cohen
authorships[3].author_position	middle
authorships[3].raw_author_name	Ezra E.W. Cohen
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5086025400
authorships[4].author.orcid	https://orcid.org/0000-0001-6528-6319
authorships[4].author.display_name	Conor Steuer
authorships[4].author_position	middle
authorships[4].raw_author_name	Conor Steuer
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5022339242
authorships[5].author.orcid	https://orcid.org/0000-0003-3156-3159
authorships[5].author.display_name	Martin Gutierrez
authorships[5].author_position	middle
authorships[5].raw_author_name	Martin Gutierrez
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5031684939
authorships[6].author.orcid	https://orcid.org/0000-0002-6677-1794
authorships[6].author.display_name	Robert Ilaria
authorships[6].author_position	middle
authorships[6].raw_author_name	Robert Ilaria
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5026351607
authorships[7].author.orcid	https://orcid.org/0000-0001-6234-6435
authorships[7].author.display_name	Brenda O’Connell
authorships[7].author_position	last
authorships[7].raw_author_name	Brenda O'Connell
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5058775398
authorships[8].author.orcid	https://orcid.org/0000-0002-6032-4870
authorships[8].author.display_name	Joanna Peng
authorships[8].author_position	middle
authorships[8].raw_author_name	Joanna Peng
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5088455303
authorships[9].author.orcid	https://orcid.org/0000-0003-3351-6794
authorships[9].author.display_name	Nora Zizlsperger
authorships[9].author_position	middle
authorships[9].raw_author_name	Nora Zizlsperger
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5060992997
authorships[10].author.orcid	https://orcid.org/0000-0002-6322-9721
authorships[10].author.display_name	Anthony W. Tolcher
authorships[10].author_position	middle
authorships[10].raw_author_name	Anthony Tolcher
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5054656505
authorships[11].author.orcid	https://orcid.org/0000-0001-6718-2222
authorships[11].author.display_name	Jedd D. Wolchok
authorships[11].author_position	middle
authorships[11].raw_author_name	Jedd D. Wolchok
authorships[11].is_corresponding	False
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://aacr.figshare.com/articles/journal_contribution/Table_S2_from_Eganelisib_a_First-in-Class_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors_Results_of_the_Phase_1_1b_MARIO-1_Trial/30706743/1/files/59831172.pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-11-25T00:00:00
display_name	Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
has_fulltext	False
is_retracted	False
updated_date	2025-11-28T20:18:18.741253
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1078-0432.30706743
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Table_S2_from_Eganelisib_a_First-in-Class_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors_Results_of_the_Phase_1_1b_MARIO-1_Trial/30706743/1/files/59831172.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.30706743
primary_location.id	doi:10.1158/1078-0432.30706743
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Table_S2_from_Eganelisib_a_First-in-Class_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors_Results_of_the_Phase_1_1b_MARIO-1_Trial/30706743/1/files/59831172.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.30706743
publication_date	2025-11-25
publication_year	2025
referenced_works_count	0
abstract_inverted_index.in	5
abstract_inverted_index.of	1
abstract_inverted_index.and	11
abstract_inverted_index.with	8
abstract_inverted_index.treated	7
abstract_inverted_index.activity	3
abstract_inverted_index.patients	6
abstract_inverted_index.endpoints	4
abstract_inverted_index.anti-tumor	2
abstract_inverted_index.eganelisib	9
abstract_inverted_index.combination	12
abstract_inverted_index.monotherapy	10
abstract_inverted_index.<p>Summary	0
abstract_inverted_index.therapy</p>	13
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	12
citation_normalized_percentile